UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2018
DOUGHERTY’S PHARMACY, INC.
(Exact name of registrant as specified in its charter)
Commission File Number:000-27945
| Delaware | 75-2900905 |
| (State or other jurisdiction | (IRS Employer |
| of incorporation) | Identification No.) |
5924 ROYAL LANE, SUITE 250
DALLAS, TEXAS 75230
(Address of principal executive offices and Zip Code)
Registrant’s telephone number, including area code: 972-250-0945
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240. 12b-2).
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Dougherty’s Pharmacy, Inc. (the “Company”) issued a press release on May 22, 2018, relating to the adjournment of its Annual Meeting to June 12, 2018, at 1:30 PM, to be held at the Company’s Corporate Offices located at 5924 Royal Lane, Suite 250, Dallas, Texas, 75230.
The Annual Meeting was adjourned in order to provide additional time for the Company to obtain a quorum, which was not present on May 16, 2018, the date of the originally scheduled Annual Meeting.
No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting.
| Item 9.01 | Financial Statements and Exhibits |
(d) The following exhibit is furnished herewith:
99.1 Press Release Dated May 22, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 22, 2018
| | Dougherty’s Pharmacy, Inc. |
| | |
| | By: | /s/ James C. Leslie |
| | | James C. Leslie Chairman, Chief Executive Officer, Interim President, and Interim Chief Financial Officer (Duly Authorized Principal Executive Officer and Principal Financial Officer) |
